Retracted Article: Long non-coding RNA PCAT1 facilitates cell growth in multiple myeloma through an MTDH-mediated AKT/β-catenin signaling pathway by sponging miR-363-3p

Chen, Ying; Hao, Jinxia; Zhao, Jing; Liu, Ye; Li, Yuan; Ren, Juan; Wang, Wei

doi:10.1039/c9ra06188f

Cited by 2 publications

(2 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Additionally, enhanced lnc‐PCAT1 promotes plasma cell proliferation and inhibits apoptosis by downregulating microRNA‐129 (miR‐129) and further regulating mitogen‐activated protein kinase kinase kinase 7/nuclear factor‐kappaB (MAP3K7/NF‐κB) pathways in MM 12 . Moreover, via modulating the protein kinase B/β‐catenin signaling pathway, lnc‐PCAT1 facilitates plasma cell proliferation, thus participating in the occurrence and progression of MM 13 . Based on the above‐mentioned information, we hypothesized that lnc‐PCAT1 might be a potential biomarker for MM.…”

Section: Introductionmentioning

confidence: 99%

“… 12 Moreover, via modulating the protein kinase B/β‐catenin signaling pathway, lnc‐PCAT1 facilitates plasma cell proliferation, thus participating in the occurrence and progression of MM. 13 Based on the above‐mentioned information, we hypothesized that lnc‐PCAT1 might be a potential biomarker for MM. However, no previous studies have been performed on this.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Baseline lncRNA PCAT1 high expression and its longitude increment during induction therapy predict worse prognosis in multiple myeloma patients

Zhao

2021

Clinical Laboratory Analysis

View full text Add to dashboard Cite

Background Long noncoding RNA PCAT1 (lnc‐PCAT1) involves in the proliferation and drug sensitivity of multiple myeloma (MM), while its prognostic role in MM patients is still obscure. This study aimed to explore the association of lnc‐PCAT1 with MM risk, clinical characteristics, treatment response, progression‐free survival (PFS), and overall survival (OS). Methods A total of 83 symptomatic MM patients were enrolled in this study. Additionally, 30 healthy bone marrow donors as health controls were also recruited. Bone marrow plasma cell samples of MM patients and health donors were collected. Lnc‐PCAT1 in bone marrow plasma cells was detected by reverse transcription‐quantitative polymerase chain reaction. Results Lnc‐PCAT1 was increased in MM patients than in health donors (p < 0.001), and receiver operating characteristic (ROC) curve showed that lnc‐PCAT1 had excellent capability of discriminating MM patients from health donors (area under curve: 0.932, 95% confidence interval: 0.889–0.976). In MM patients, lnc‐PCAT1 was correlated with bone lesion (p = 0.024), higher β2‐MG (p = 0.005), LDH (p = 0.037), and presence of Del (17p) (p = 0.029). Lnc‐PCAT1 was also associated with poor ISS stage (p = 0.013) and R‐ISS stage (p = 0.005). Besides, lnc‐PCAT1 was reduced after treatment (p < 0.001); meanwhile, lnc‐PCAT1 before treatment was correlated with lower CR (p = 0.046) but not ORR (p = 0.185). Additionally, lnc‐PCAT1 after treatment was associated with lower CR (p = 0.003) and ORR (p = 0.010). Furthermore, baseline Inc‐PCAT1 high and Inc‐PCAT1 increase after treatment were correlated with worse PFS and OS (all p < 0.05). Conclusion Lnc‐PCAT1 dysregulation serves as a biomarker for diagnosis and prognosis for MM.

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%